Ask Indegene (Beta)
Online
🧠 Building on our previous conversation...
Hello, how can I help you today?
You may type your question or choose from the options below:
Explore Solutions
Browse Insights
View Case Studies
Read Latest News
Explore Careers
Connect with an Expert
Thank you!
We'll be in touch. In the meantime, feel free to keep exploring!
#FutureReadyHealthcare
Share this blog
17 Jul 2025
Designs like Nike's distinctive 'swoosh' and McDonald's recognizable 'golden arches' are etched into our minds. Good design, whether for a simple post-it or a complex pharmaceutical product, has the potential to impact human lives.
In fact, according to a McKinsey report, companies that excel at design grow revenues and shareholder returns at nearly twice the rate of their industry peers.
In pharma content design processes, designers have had to communicate complex information clearly and concisely while navigating the intricate regulatory landscape. Yet, their potential is often constrained by complexities such as demanding collaboration, profound user understanding, and regulatory adherence.
To streamline, accelerate, and scale the design process, numerous organizations have started developing global design systems, and until recently, there was no consensus on the platforms used to create these design systems among organizations and external agencies. Following Adobe’s acquisition of Figma and the discontinuation of XD, pharma teams are rapidly adopting Figma as the preferred design platform for life sciences.
While this unexpected shift might appear nuanced, even tedious initially, it ushers in a host of opportunities for pharmaceutical companies to enhance efficiency and speed by strengthening their UX design processes.
This article delves into how organizations’ internal UX design teams and vendor partners can seamlessly embrace Figma. It also explores how Figma design could gradually help rectify the slow and fragmented design operations in the pharmaceutical industry and accelerate the adoption and implementation of robust design processes.
7 Benefits of Figma Design for Pharma Content
Figma design is reshaping the pharma content design process by enabling faster collaboration, compliance, and creativity. From pharmaceutical packaging design to digital assets and labels, teams can now work seamlessly at scale. Below are 7 benefits of Figma design.
1. Figma boosts design efficiency
Pharma companies often rely on an agency of record (AOR), brand teams, and production partners to work collaboratively to meet their design requirements across audience groups, geographies, and markets. As a result, establishing a truly collaborative design process is challenging due to the variation in tools used by different entities involved.
With all members adopting Figma, multiple designers, and reviewers can work on a single live file simultaneously, mitigating version conflicts and duplicate efforts. Moreover, Figma allows non-design team members to participate in the end-to-end design process, eliminating transparency issues and encouraging innovation. This enables organizations to foster a culture of collaboration that enhances efficiency, accelerates speed-to-market, and eliminates redundancies.
Read how a pharma major reduced its time-to-market with an efficient global design system.
2. Ensures Security and Regulatory Compliance
Confidentiality and compliance are paramount in the pharmaceutical industry. Figma eases this concern with Figma SOC 2 Type II audit certification —a recognized security and compliance standard for software companies in the United States. Notably, Figma meets key regulatory expectations globally, being among a select group of 17 companies to receive compliance certification from the EU Cloud Code of Conduct, the gold standard for data protection in Europe's cloud sector.
3. Cost-Effective Design Efficiency
In the case of larger organizations, Figma’s enterprise license provides access to multiple teams, enabling design systems and assets to be accessed by a larger community. The platform's dashboard view helps organizations track high and low-performing assets, thus, driving temporal and cost efficiencies.
For smaller organizations, Figma's free view license enables AORs to add the company's team members as reviewers. And with multiple non-designers involved in the design process, Figma drives better cost-savings for the entire ecosystem compared to other platforms.
4. Driving Modular Content at Scale
The growing need for personalized experiences among physicians and patients has prompted several organizations to build capabilities to adopt modular content in a scalable and sustainable manner. A modular content approach transforms overall content operations by enhancing content reuse and efficiency. And Figma greatly enhances this capability. By seamlessly integrating with an organization's digital asset management system, Figma assimilates content modules, templates, or even existing assets, tailoring them to suit the preferences of the target audience. Furthermore, content marketers can make real-time edits in an Excel sheet linked to a Figma design file, bypassing the need for comments on PDFs or Word documents. Finally, by enabling reviewers to appraise, annotate, and collaborate on the fly, Figma improves the efficiency of the medical, legal, and regulatory affairs (MLR) review process, enabling a faster time-to-market.
5. Simplified Adoption and Ease-of-Use
Figma is known for its user-friendly and intuitive interface, making it easy for all members of the content and design ecosystem to adopt and master it. Figma has also fostered a substantial community of designers to create a database of user-designed interfaces, widgets, plugins, add-ons, and applications. This eases the learning curve for new designers by offering enriching access to resources and robust support from a vibrant community of global design experts.
6. Tailored to Fit and Customizable by Design
Every organization operates with distinct processes and technological infrastructure. To ensure that Figma blends seamlessly into its existing ecosystem, organizations can customize the platform by utilizing several paid and free plugins available in Figma’s library. If a particular plugin is unavailable in Figma’s library, organizations can also collaborate with developers to create bespoke solutions, in a cost-effective manner.
7. Smooth and Seamless Migration
Figma now offers a range of updated plugins and native features that enable seamless file migration from Adobe XD, Adobe Cloud, and Sketch. With Adobe XD discontinued, many teams have already transitioned their design assets to Figma using its built-in import tools or community-supported plugins. While older, in-progress projects may still be completed in their original platforms, new workflows are increasingly being centralized in Figma to ensure consistency, collaboration, and long-term support.
Although the transition to Figma may entail temporal and financial implications for design systems during the initial transition and setup phase, the subsequent, significant efficiency gains and cost savings far outweigh these and render it a prudent and far-sighted choice in the long run.
Innovative Pharma Content Design with Figma
Design influences every facet of the pharmaceutical industry, from drug development and clinical trials to pharmaceutical packaging design, labeling, branding, and regulatory compliance.
As the pharma content design process becomes more complex and collaborative, Figma design offers a unified, efficient, and secure solution. With its intuitive interface, Figma SOC 2 compliance, and real-time collaboration features, it empowers global teams to accelerate innovation, enhance content quality, and maintain regulatory standards, making it a strategic enabler of modern, scalable pharma design excellence.
Contact us for a strategic consultation today!
Share this blog
Get exclusive pharma
insights delivered to your inbox
Latest
Latest
